ForSight VISION5 Sees $9.3M

Menlo Park-based ForSight VISION5 said Monday that it has closed its $9.3M, Series B-1 funding round. The firm, which is an offshoot of ophthalmic technology incubator Forsight Labs, said VISION5 is focused on treatments for ocular hypertension and glaucoma. The funding came from Technology Partners, Delphi Ventures, investors Morgenthaler Ventures and Versant Ventures. As part of the funding, the firm said it named John F. Maroney as President, CEO, and Director of the company; Maroney was most recently at EndoTex Interventional Systems. More information »